Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NYSE:MNK
- CUSIP: N/A
- Web: www.mallinckrodt.com
Capitalization:- Market Cap: $3.46024 billion
- Outstanding Shares: 99,347,000
Average Prices:- 50 Day Moving Avg: $37.65
- 200 Day Moving Avg: $42.88
- 52 Week Range: $33.61 - $76.81
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 4.34
- P/E Growth: 0.88
Sales & Book Value:- Annual Revenue: $3.27 billion
- Price / Sales: 1.06
- Book Value: $52.46 per share
- Price / Book: 0.66
Profitability:- EBIDTA: $666.6 million
- Net Margins: 12.64%
- Return on Equity: 15.28%
- Return on Assets: 5.20%
Debt:- Debt-to-Equity Ratio: 1.05%
- Current Ratio: 1.06%
- Quick Ratio: 0.81%
Misc:- Average Volume: 2.62 million shs.
- Beta: 1.54
- Short Ratio: 7.62
Frequently Asked Questions for Mallinckrodt PLC (NYSE:MNK)
What is Mallinckrodt PLC's stock symbol?
Mallinckrodt PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How will Mallinckrodt PLC's stock buyback program work?
Mallinckrodt PLC announced that its Board of Directors has initiated a share repurchase program on Sunday, April 9th 2017, which permits the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to buy up to 18.5% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's leadership believes its shares are undervalued.
How were Mallinckrodt PLC's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) announced its quarterly earnings results on Tuesday, August, 8th. The company reported $1.85 earnings per share for the quarter, beating analysts' consensus estimates of $1.73 by $0.12. The company had revenue of $824.50 million for the quarter, compared to analysts' expectations of $829.56 million. Mallinckrodt PLC had a return on equity of 15.28% and a net margin of 12.64%. The company's quarterly revenue was down 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.03 EPS. View Mallinckrodt PLC's Earnings History.
When will Mallinckrodt PLC make its next earnings announcement?
What guidance has Mallinckrodt PLC issued on next quarter's earnings?
Mallinckrodt PLC updated its FY17 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of $7.40-8.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.53.
Where is Mallinckrodt PLC's stock going? Where will Mallinckrodt PLC's stock price be in 2017?
16 brokerages have issued 12-month target prices for Mallinckrodt PLC's stock. Their forecasts range from $40.00 to $98.00. On average, they expect Mallinckrodt PLC's share price to reach $63.22 in the next twelve months. View Analyst Ratings for Mallinckrodt PLC.
What are analysts saying about Mallinckrodt PLC stock?
Here are some recent quotes from research analysts about Mallinckrodt PLC stock:
- 1. According to Zacks Investment Research, "Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures. The company sold its Nuclear Imaging business due to lingering challenging conditions for quite some time. The company also sold its Intrathecal Therapy business to focus on its key areas. Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments. The company is working on expanding Acthar's label further. The generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Weakness in shares persist as shares have underperformed the Medical-Generic Drugs industry so far in 2017." (7/27/2017)
- 2. Mizuho analysts commented, "We reiterate our Buy rating and $73 PT and push back against short-seller inaccuracies and Acthar pricing concerns." (5/31/2017)
- 3. Guggenheim analysts commented, "Although any potential competition for MNK's largest single drug, Acthar, is a concern, we think that it will take at least several years for Marathon to even establish proof of concept for its product, which means there is no near-to-mid-term threat here. We forecast Acthar sales of $1.2B in '16 and total MNK sales of $3.3B. We believe that MNK's execution of its stated business objectives is underappreciated and would note that the company has a demonstrated record of success, supported by consistent earnings beats over the last five quarters. We continue to believe strong execution of MNK's growth initiatives will drive P/E multiple expansion (from 6x to at least 10x, average pharma trough multiple) and put MNK shares back on a path to $70+." (1/19/2017)
Who are some of Mallinckrodt PLC's key competitors?
Some companies that are related to Mallinckrodt PLC include ConvaTec Group PLC (CTEC), Advanced Accelerator Applications S.A. (AAAP), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Aimmune Therapeutics (AIMT), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), NOVAN INC (NOVN), Check-Cap (CHEK), CorMedix (CRMD), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are Mallinckrodt PLC's key executives?
Mallinckrodt PLC's management team includes the folowing people:
- Melvin D. Booth Ph.D., CPA, Independent Chairman of the Board
- Mark C. Trudeau, President, Chief Executive Officer, Director
- Matthew K. Harbaugh, Chief Financial Officer, Executive Vice President
- Ian J. Watkins, Chief Human Resource Officer
- Ronald K. Lloyd, Executive Vice President and President - Hospital Therapies
- Gary M. Phillips M.D., Executive Vice President and Chief Strategy Officer
- Steven Romano, Executive Vice President and Chief Scientific Officer
- Frank Scholz, Executive Vice President of Global Operations and President - Specialty Generics
- Hugh O'Neill, Senior Vice President and President - Autoimmune and Rare Diseases
- Raymond J. Furey, Chief Compliance Officer
Who owns Mallinckrodt PLC stock?
Mallinckrodt PLC's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.04%), BlackRock Inc. (8.02%), Paulson & CO. Inc. (7.09%), State Street Corp (5.09%), Alliancebernstein L.P. (3.37%) and HealthCor Management L.P. (2.42%). Company insiders that own Mallinckrodt PLC stock include Coleman N Lannum III, Gary M Phillips, Hugh M O'neill, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Institutional Ownership Trends for Mallinckrodt PLC.
Who sold Mallinckrodt PLC stock? Who is selling Mallinckrodt PLC stock?
Mallinckrodt PLC's stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., BlackRock Inc., Acadian Asset Management LLC, Royal Bank of Canada, Paulson & CO. Inc., Vanguard Group Inc., GAM Holding AG and Northern Trust Corp. View Insider Buying and Selling for Mallinckrodt PLC.
Who bought Mallinckrodt PLC stock? Who is buying Mallinckrodt PLC stock?
Mallinckrodt PLC's stock was purchased by a variety of institutional investors in the last quarter, including HealthCor Management L.P., Janus Henderson Group PLC, Ameriprise Financial Inc., AJO LP, Dimensional Fund Advisors LP, FMR LLC, Alliancebernstein L.P. and LSV Asset Management. Company insiders that have bought Mallinckrodt PLC stock in the last two years include Coleman N Lannum III, Gary M Phillips, Hugh M O'neill, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Insider Buying and Selling for Mallinckrodt PLC.
How do I buy Mallinckrodt PLC stock?
Shares of Mallinckrodt PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mallinckrodt PLC's stock price today?
One share of Mallinckrodt PLC stock can currently be purchased for approximately $34.83.
MarketBeat Community Rating for Mallinckrodt PLC (NYSE MNK)MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Mallinckrodt PLC (NYSE:MNK) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 13 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.81) |
| Consensus Price Target: | $63.22 (81.51% upside) |
Analysts' Ratings History for Mallinckrodt PLC (NYSE:MNK)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/19/2017 | Oppenheimer Holdings, Inc. | Lower Price Target | | $70.00 -> $48.00 | Low |  |
| 9/15/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $67.00 | Low | |
| 9/14/2017 | Deutsche Bank AG | Reiterated Rating | Buy | $56.00 -> $45.00 | Low | |
| 9/14/2017 | Citigroup Inc. | Lower Price Target | Reduce -> Buy | $45.00 | Low | |
| 9/13/2017 | Mizuho | Downgrade | Buy -> Neutral | $70.00 -> $40.00 | Medium | |
| 9/5/2017 | Cantor Fitzgerald | Reiterated Rating | Buy | $52.00 | Low | |
| 9/6/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $85.00 | Low | |
| 9/6/2017 | Morgan Stanley | Downgrade | Overweight -> Equal Weight | $65.00 -> $40.00 | Low | |
| 8/25/2017 | Jefferies Group LLC | Lower Price Target | Buy | $70.00 -> $60.00 | Low | |
| 8/9/2017 | BMO Capital Markets | Reiterated Rating | Outperform | $69.00 -> $65.00 | Low | |
| 8/9/2017 | Raymond James Financial, Inc. | Lower Price Target | Outperform | $65.00 -> $58.00 | Low | |
| 8/8/2017 | Canaccord Genuity | Set Price Target | Buy | $87.00 | High | |
| 6/21/2017 | Wells Fargo & Company | Reiterated Rating | Outperform | $83.50 | High | |
| 4/1/2017 | Guggenheim | Set Price Target | Buy | $98.00 | Low | |
| 3/20/2017 | Leerink Swann | Reiterated Rating | Outperform | | Low | |
| 1/25/2017 | J P Morgan Chase & Co | Set Price Target | Hold | $78.00 | N/A | |
| 8/26/2016 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Neutral | $83.00 | N/A | |
| 8/25/2016 | Barclays PLC | Reiterated Rating | Overweight | $88.00 | N/A | |
| 3/16/2016 | Northland Securities | Reiterated Rating | Buy | $95.00 | N/A | |
| 2/2/2016 | Nomura | Reiterated Rating | Neutral | $100.00 | N/A | |
| 10/7/2015 | Bank of America Corporation | Lower Price Target | Buy | $135.00 -> $131.00 | N/A | |
(Data available from 9/26/2015 forward)
Earnings History for Mallinckrodt PLC (NYSE:MNK)Earnings History by Quarter for Mallinckrodt PLC (NYSE MNK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 12/5/2017 | | | | | | | | |
| 8/8/2017 | Q2 2017 | $1.73 | $1.85 | $829.56 million | $824.50 million | View | Listen | |
| 5/8/2017 | Q1 2017 | $1.63 | $1.68 | $781.23 million | $810.90 million | View | Listen | |
| 2/7/2017 | Q117 | $1.82 | $1.91 | $827.12 million | $829.90 million | View | Listen | |
| 11/29/2016 | Q416 | $1.98 | $2.04 | $880.10 million | $887.20 million | View | Listen | |
| 8/2/2016 | Q316 | $2.01 | $2.20 | $920.35 million | $970.60 million | View | Listen | |
| 5/3/2016 | Q216 | $1.72 | $2.01 | $878.70 million | $918.00 million | View | Listen | |
| 2/2/2016 | Q116 | $1.78 | $2.09 | $888.33 million | $915.00 million | View | Listen | |
| 11/23/2015 | Q415 | $1.77 | $1.84 | $869.41 million | $882.40 million | View | Listen | |
| 8/4/2015 | Q315 | $1.82 | $2.05 | $983.81 million | $965.10 million | View | Listen | |
| 5/5/2015 | Q215 | $1.48 | $1.72 | $860.89 million | $909.90 million | View | Listen | |
| 2/3/2015 | Q115 | $1.57 | $1.84 | $880.12 million | $866.00 million | View | Listen | |
| 11/19/2014 | Q414 | $1.41 | $1.68 | $759.04 million | $789.00 million | View | Listen | |
| 8/7/2014 | Q314 | $0.86 | $1.20 | $278.80 million | $653.10 million | View | Listen | |
| 5/8/2014 | Q214 | $0.79 | $0.95 | $566.50 million | $557.80 million | View | Listen | |
| 2/6/2014 | Q1 | $0.66 | $0.88 | $539.24 million | $540.20 million | View | Listen | |
| 11/7/2013 | | $0.85 | $1.02 | $572.57 million | $552.20 million | View | Listen | |
| 8/9/2013 | Q3 2013 | $0.78 | $0.49 | $557.22 million | $570.00 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Mallinckrodt PLC (NYSE:MNK)2017 EPS Consensus Estimate: $7.55
2018 EPS Consensus Estimate: $8.27
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $1.54 | $1.84 | $1.71 |
| Q2 2017 | 3 | $1.70 | $1.95 | $1.80 |
| Q3 2017 | 3 | $1.88 | $1.89 | $1.89 |
| Q4 2017 | 3 | $2.02 | $2.35 | $2.16 |
| Q1 2018 | 3 | $1.66 | $2.06 | $1.85 |
| Q2 2018 | 1 | $1.91 | $1.91 | $1.91 |
| Q3 2018 | 1 | $2.03 | $2.03 | $2.03 |
| Q4 2018 | 1 | $2.48 | $2.48 | $2.48 |
(Data provided by Zacks Investment Research)
Dividend History for Mallinckrodt PLC (NYSE:MNK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Mallinckrodt PLC (NYSE:MNK)Insider Ownership Percentage: 0.53%
Institutional Ownership Percentage: 97.40%
Insider Trades by Quarter for Mallinckrodt PLC (NYSE:MNK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/30/2017 | Meredith B. Fischer | Insider | Buy | 1,280 | $39.63 | $50,726.40 | |
| 6/9/2017 | Steven J. Romano | VP | Buy | 1,000 | $39.88 | $39,880.00 | |
| 6/8/2017 | Hugh M. O'neill | VP | Buy | 1,000 | $40.24 | $40,240.00 | |
| 6/5/2017 | Coleman N Lannum III | VP | Buy | 500 | $39.33 | $19,665.00 | |
| 6/2/2017 | Coleman N Lannum III | VP | Buy | 1,350 | $42.89 | $57,901.50 | |
| 5/12/2017 | Coleman N. Lannum III | VP | Buy | 1,968 | $46.20 | $90,921.60 | |
| 3/10/2017 | Matthew K. Harbaugh | CFO | Buy | 600 | $49.19 | $29,514.00 | |
| 3/7/2017 | Michael-Bryant Hicks | General Counsel | Buy | 290 | $50.35 | $14,601.50 | |
| 2/23/2017 | Meredith B. Fischer | Insider | Buy | 2,000 | $54.34 | $108,680.00 | |
| 2/14/2017 | Mark Trudeau | Insider | Buy | 1,000 | $50.47 | $50,470.00 | |
| 2/10/2017 | Steven J. Romano | VP | Buy | 1,000 | $49.68 | $49,680.00 | |
| 5/10/2016 | Hugh M O'neill | VP | Buy | 1,653 | $60.99 | $100,816.47 | |
| 5/10/2016 | Matthew K Harbaugh | CFO | Buy | 500 | $59.37 | $29,685.00 | |
| 5/6/2016 | Mark Trudeau | CEO | Buy | 1,000 | $56.02 | $56,020.00 | |
| 5/6/2016 | Steven J Romano | VP | Buy | 900 | $56.00 | $50,400.00 | |
| 3/4/2016 | Coleman N Lannum III | VP | Buy | 2,600 | $62.63 | $162,838.00 | |
| 2/26/2016 | Meredith B Fischer | VP | Buy | 1,400 | $69.80 | $97,720.00 | |
| 2/12/2016 | Coleman N Lannum III | VP | Buy | 600 | $59.66 | $35,796.00 | |
| 2/10/2016 | Coleman N Lannum III | VP | Buy | 1,300 | $62.58 | $81,354.00 | |
| 2/9/2016 | Matthew K. Harbaugh | CFO | Buy | 1,300 | $63.00 | $81,900.00 | |
| 2/8/2016 | Coleman N. Lannum III | VP | Buy | 800 | $66.37 | $53,096.00 | |
| 12/22/2015 | Coleman N Lannum III | SVP | Buy | 500 | $72.50 | $36,250.00 | |
| 12/11/2015 | Terrance L Carlson | General Counsel | Buy | 1,000 | $69.10 | $69,100.00 | |
| 12/2/2015 | Gary M. Phillips | VP | Buy | 1,000 | $72.17 | $72,170.00 | |
| 11/30/2015 | Mark Trudeau | CEO | Buy | 1,350 | $65.89 | $88,951.50 | |
| 11/27/2015 | Coleman N Lannum III | SVP | Buy | 1,200 | $66.86 | $80,232.00 | |
| 11/27/2015 | Meredith B Fischer | VP | Buy | 2,200 | $66.93 | $147,246.00 | |
| 11/27/2015 | Terrance L Carlson | General Counsel | Buy | 1,000 | $66.54 | $66,540.00 | |
| 8/25/2015 | Hugh M O'neill | SVP | Buy | 1,197 | $83.52 | $99,973.44 | |
| 8/25/2015 | Mark Trudeau | CEO | Buy | 1,000 | $83.08 | $83,080.00 | |
| 8/21/2015 | Coleman N Lannum III | SVP | Buy | 2,375 | $88.52 | $210,235.00 | |
| 8/21/2015 | Mark Trudeau | CEO | Buy | 2,000 | $88.45 | $176,900.00 | |
| 6/4/2015 | Coleman N Lannum III | VP | Buy | 1,300 | $126.41 | $164,333.00 | |
| 6/2/2015 | Matthew K Harbaugh | CFO | Sell | 22,106 | $128.64 | $2,843,715.84 | |
| 5/18/2015 | Mario D Saltarelli | VP | Sell | 4,580 | $127.44 | $583,675.20 | |
| 5/13/2015 | Don M Bailey | Director | Sell | 51,417 | $122.45 | $6,296,011.65 | |
| 5/11/2015 | Sandra L Hatten | VP | Sell | 2,024 | $122.29 | $247,514.96 | |
| 4/13/2015 | Don M Bailey | Director | Sell | 40,000 | $127.61 | $5,104,400.00 | |
| 3/13/2015 | Don M Bailey | Director | Sell | 40,000 | $123.40 | $4,936,000.00 | |
| 2/13/2015 | Don M Bailey | Director | Sell | 33,891 | $114.63 | $3,884,925.33 | |
| 2/2/2015 | Mark Trudeau | CEO | Sell | 11,925 | $105.94 | $1,263,334.50 | |
| 1/9/2015 | Mark Trudeau | CEO | Sell | 15,720 | $102.00 | $1,603,440.00 | |
| 12/22/2014 | Peter G Edwards | VP | Sell | 1,265 | $99.69 | $126,107.85 | |
| 12/18/2014 | Mark Trudeau | CEO | Sell | 13,831 | $93.59 | $1,294,443.29 | |
| 9/10/2014 | Raymond J Furey | VP | Sell | 5,441 | $85.90 | $467,381.90 | |
| 9/8/2014 | Don M Bailey | Director | Sell | 221,177 | $85.23 | $18,850,915.71 | |
| 9/5/2014 | Raymond J Furey | VP | Sell | 15,000 | $85.47 | $1,282,050.00 | |
| 9/5/2014 | Virgil D Thompson | Director | Sell | 25,000 | $83.76 | $2,094,000.00 | |
| 9/2/2014 | Raymond J Furey | VP | Sell | 10,303 | $81.61 | $840,827.83 | |
| 8/29/2014 | Raymond J Furey | VP | Sell | 4,840 | $80.90 | $391,556.00 | |
| 8/19/2014 | Joseph A Zaccagnino | Director | Buy | 3,000 | $71.06 | $213,180.00 | |
| 8/13/2014 | Paulson & Co Inc | Major Shareholder | Buy | 132,100 | $69.80 | $9,220,580.00 | |
| 8/12/2014 | J Martin Carroll | Director | Buy | 2,000 | $69.24 | $138,480.00 | |
| 8/12/2014 | Paulson & Co Inc | Major Shareholder | Buy | 467,900 | $68.78 | $32,182,162.00 | |
| 8/11/2014 | Paulson & Co Inc | Major Shareholder | Buy | 207,900 | $69.70 | $14,490,630.00 | |
| 8/7/2014 | Paulson & Co Inc | Major Shareholder | Buy | 700,200 | $70.15 | $49,119,030.00 | |
| 8/1/2014 | Paulson & Co Inc | Major Shareholder | Buy | 275,000 | $69.60 | $19,140,000.00 | |
| 6/11/2014 | Melvin D Booth | Director | Buy | 4,000 | $76.05 | $304,200.00 | |
| 5/9/2014 | Paulson & Co Inc | major shareholder | Buy | 786,207 | $73.63 | $57,888,421.41 | |
| 2/3/2014 | Mark Trudeau | CEO | Sell | 14,890 | $56.12 | $835,626.80 | |
(Data available from 1/1/2013 forward)
Headline Trends for Mallinckrodt PLC (NYSE:MNK)
Latest Headlines for Mallinckrodt PLC (NYSE:MNK)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to Mallinckrodt Plc : September 25, 2017
finance.yahoo.com - September 25 at 7:28 PM |
| Mallinckrodt Completes Acquisition of InfaCare Pharmaceutical Corporation and Stannsoporfin, its Proprietary Therapy in Late-Stage Development for Newborns at Risk for Severe Jaundice
finance.yahoo.com - September 25 at 7:28 PM |
| Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United States
finance.yahoo.com - September 23 at 8:17 AM |
 | Oppenheimer Holdings Brokers Decrease Earnings Estimates for Mallinckrodt PLC (MNK)
www.americanbankingnews.com - September 21 at 1:44 PM |
 | Interesting MNK Put And Call Options For November 17th - Nasdaq
www.nasdaq.com - September 20 at 6:23 AM |
| Mallinckrodt Announces Election Of David Norton To Its Board Of Directors
finance.yahoo.com - September 20 at 6:23 AM |
| Mallinckrodt PLC (MNK) Price Target Lowered to $48.00 at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 19 at 3:52 PM |
 | Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Horizon ...
www.prnewswire.com - September 18 at 11:02 PM |
 | Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Horizon Pharma, Mylan, and Neurocrine Biosciences
www.bizjournals.com - September 18 at 11:02 PM |
| Mallinckrodt PLC (MNK) and Its Competitors Head to Head Contrast
www.americanbankingnews.com - September 18 at 4:28 AM |
| Mallinckrodt PLC (MNK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 17 at 6:38 AM |
| Piper Jaffray Companies Reaffirms Buy Rating for Mallinckrodt PLC (MNK)
www.americanbankingnews.com - September 15 at 5:32 PM |
 | Mallinckrodt (MNK): Cutting PT After Negative Ruling - Deutsche Bank - StreetInsider.com
www.streetinsider.com - September 14 at 9:08 PM |
| ETFs with exposure to Mallinckrodt Plc : September 14, 2017
finance.yahoo.com - September 14 at 9:08 PM |
| Mallinckrodt PLC (MNK) Given Buy Rating at Deutsche Bank AG
www.americanbankingnews.com - September 14 at 3:32 PM |
| Mallinckrodt PLC (MNK) PT Lowered to $45.00 at Citigroup Inc.
www.americanbankingnews.com - September 14 at 9:34 AM |
| Mizuho Securities Downgrades Mallinckrodt plc (MNK) to Neutral, Negatively Revises EPS Estimates
www.streetinsider.com - September 14 at 7:51 AM |
| Mallinckrodt Plc :MNK-US: Earnings Analysis: Q3, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 7:51 AM |
| Mallinckrodt PLC (MNK) Downgraded by Mizuho
www.americanbankingnews.com - September 13 at 8:05 AM |
| The most respected medical journal in the US just eviscerated a drug that's cost taxpayers over $1 billion
finance.yahoo.com - September 13 at 6:38 AM |
| Mallinckrodt PLC (MNK) Downgraded by Morgan Stanley
www.americanbankingnews.com - September 10 at 7:34 PM |
| Mallinckrodt PLC's (MNK) Buy Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - September 10 at 7:02 PM |
| Mallinckrodt Enters Oversold Territory (MNK)
www.nasdaq.com - September 8 at 5:25 AM |
| A furious employee is suing drugmaker Mallinckrodt over claims about its $38,000-a-dose blockbuster
finance.yahoo.com - September 8 at 5:25 AM |
| Morgan Stanley Downgrades Mallinckrodt plc (MNK) to Equalweight - StreetInsider.com
www.streetinsider.com - September 7 at 5:58 AM |
 | Mallinckrodt: Inomax Ruling Cranks Up The Pressure - Seeking Alpha
seekingalpha.com - September 7 at 5:58 AM |
| Mallinckrodt Down as District Court Invalidates Inomax Patents
finance.yahoo.com - September 7 at 5:57 AM |
| Mallinckrodt PLC's (MNK) Buy Rating Reaffirmed at UBS AG
www.americanbankingnews.com - September 6 at 3:56 PM |
| Mallinckrodt PLC (MNK) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - September 6 at 3:20 PM |
| Mizuho Reiterates "Buy" Rating for Mallinckrodt PLC (MNK)
www.americanbankingnews.com - September 6 at 9:33 AM |
| Mallinckrodt (MNK) Sell-Off 'Excessive' - Mizuho - StreetInsider.com
www.streetinsider.com - September 5 at 9:38 PM |
| The Stock Market Gets Smashed -- Here Are Some Terrible Performers
finance.yahoo.com - September 5 at 4:34 PM |
| Mallinckrodt is getting crushed after a judge invalidated many of its patents
finance.yahoo.com - September 5 at 4:34 PM |
| Wall Street's most hated pharma company just lost a lifeline
finance.yahoo.com - September 5 at 4:34 PM |
| ValuEngine Downgrades Mallinckrodt PLC (MNK) to Hold
www.americanbankingnews.com - September 2 at 10:00 PM |
| Meredith B. Fischer Acquires 1,280 Shares of Mallinckrodt PLC (MNK) Stock
www.americanbankingnews.com - September 1 at 10:34 AM |
| Q1 2018 Earnings Forecast for Mallinckrodt PLC (MNK) Issued By Jefferies Group
www.americanbankingnews.com - August 28 at 4:26 AM |
| Financial Comparison: Mallinckrodt PLC (MNK) and Rockwell Medical (RMTI)
www.americanbankingnews.com - August 27 at 6:08 PM |
| Mallinckrodt PLC (MNK) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - August 25 at 7:10 PM |
| Mallinckrodt PLC (MNK) Price Target Cut to $60.00
www.americanbankingnews.com - August 25 at 11:06 AM |
| Mallinckrodt (MNK): LBO Possibility Becoming More Likely - Jefferies - StreetInsider.com
www.streetinsider.com - August 25 at 8:39 AM |
| Mallinckrodt PLC (MNK) Downgraded by BidaskClub to Strong Sell
www.americanbankingnews.com - August 18 at 9:32 PM |
 | Analyst: Mallinckrodt Stock Is Undervalued - Benzinga
www.benzinga.com - August 17 at 8:37 PM |
| Mallinckrodt: FDA Chief Comments Are Another Negative - Seeking Alpha
seekingalpha.com - August 17 at 3:34 PM |
| Analyst: Mallinckrodt Stock Is Undervalued
finance.yahoo.com - August 17 at 3:58 AM |
| Mallinckrodt Plc – Value Analysis (NYSE:MNK) : August 17, 2017
finance.yahoo.com - August 17 at 3:58 AM |
| Mallinckrodt To Present At Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - August 16 at 6:14 AM |
| Mallinckrodt (MNK) Looks Strong on Acthar, Generics Weak
finance.yahoo.com - August 16 at 6:13 AM |
| Mallinckrodt PLC to Post FY2018 Earnings of $7.86 Per Share, Cantor Fitzgerald Forecasts (MNK)
www.americanbankingnews.com - August 14 at 8:36 AM |
| Mallinkcrodt Confidence Is Starting To Crack - Seeking Alpha
seekingalpha.com - August 13 at 12:58 AM |
Mallinckrodt PLC (MNK) Chart for Tuesday, September, 26, 2017
